|
 The company's shares were up 3 percent at 4381 pence at 12.52 GMT on
the London Stock Exchange on Wednesday. Shire's U.S.-listed shares
were up 3 percent at $176.28 in light premarket trading on the
Nasdaq.
Shire, which sells Vyvanse and Intuniv to treat
Attention-deficit/Hyperactivity Disorder (ADHD), has focused on
developing treatments for the condition that affects about 4 percent
of the U.S. population.
Data showed both doses of the experimental drug, SHP465, were better
than a placebo in treating patients with
Attention-deficit/Hyperactivity Disorder, Shire said.
Shire, which sponsored an awareness campaign on ADHD that included
Maroon 5 singer Adam Levine in 2011, said if SHP465 was approved by
the FDA, the company's ADHD drug franchise would be protected up to
2029.
The company said it was on track to get the drug approved by the
U.S. Food and Drug Administration in the second half of 2017.
Shire, which is still integrating its acquisition of Baxalta, had
reported in April similar results from a late-stage safety and
efficacy study.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian
and Saumyadeb Chakrabarty)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
